Drug insight: Rituximab in renal disease and transplantation

Nature Clinical Practice Nephrology

Volumn 2, Issue 4, 2006, Pages 221-230

  Salama, Alan D ^a,b,c   Pusey, Charles D ^a,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Autoimmune disease; Kidney transplant; MabThera ; Rituximab

Indexed keywords

ALLOANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; TACROLIMUS;

ABDOMINAL PAIN; ADENOCARCINOMA; ANGIONEUROTIC EDEMA; ANTIBODY TITER; ANTIGEN PRESENTATION; ARTERY THROMBOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BRONCHOSPASM; CHILL; CLINICAL TRIAL; CRYOGLOBULINEMIA; CYTOTOXICITY; DYSPNEA; FEVER; GLOMERULOSCLEROSIS; HEADACHE; HERPES ZOSTER; HUMAN; HYPOTENSION; IDIOPATHIC DISEASE; IN VITRO STUDY; INFLUENZA; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MYALGIA; NEPHROTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; PURE RED CELL ANEMIA; PURPURA; RASH; REVIEW; RIGOR; SERUM SICKNESS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES; ERYTHROPOIETIN, RECOMBINANT; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GRAFT REJECTION; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOPROLIFERATIVE DISORDERS; RED-CELL APLASIA, PURE; VASCULITIS;

EID: 33646888431     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0133     Document Type: Review

References (62)

1. Anolik JH et al. (2003) The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48: 455-459
2. Teeling JL et al. (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793-1800
3. McLaughlin P et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833
4. Mohrbacher A (2005) B cell non-Hodgkin's lymphoma: rituximab safety experience. Arthritis Res Ther 7 (Suppl 3): S19-S25
5. Edwards JC et al. (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572-2581
6. Vieira CA et al. (2004) Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 77: 542-548
7. Looney RJ et al. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50: 2580-2589
8. Cohen CD et al. (2005) CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol 18: 328-333
9. Remuzzi G et al. (2002) Rituximab for idiopathic membranous nephropathy. Lancet 360: 923-924
10. Ruggenenti P et al. (2003) Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 14: 1851-1857
11. Rossi P et al. (2005) Anti-CD20 monoclonal antibody for the treatment of refractory autoimmune haemolytic anaemia associated with idiopathic membranous nephropathy. Rheumatology (Oxford) 44: 403-405
12. Benz K et al. (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19: 794-797
13. Lamprecht P et al. (2003) Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 62: 1230-1233
14. Roccatello D et al. (2004) Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 19: 3054-3061
15. Zaja F et al. (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101: 3827-3834
16. Ghijsels E et al. (2004) Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis 43: e34-e38
17. Ghobrial IM et al. (2004) Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenstrom macroglobulinemia does not indicate failure of response. Am J Hematol 77: 329-330
18. Sfikakis PP et al. (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52: 501-513
19. Leandro MJ et al. (2002) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46: 2673-2677
20. van Vollenhoven RF et al. (2004) Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 33: 423-427
21. Smith KGC et al. (2004) A prospective trial of B-cell depletion with Rituximab in refractory SLE [abstract #113]. JASN 15
22. Gottenberg J et al. (2004) Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64: 913-920
23. Marks SD et al. (2005) B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52: 3168-3174
24. Edelbauer M et al. (2005) Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report. Pediatr Nephrol 20: 811-813
25. Specks U et al. (2001) Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44: 2836-2840
26. Keogh KA et al. (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 262-268
27. Smith KGC et al. (2004) Effective treatment of refractory vasculitis by B cell depletion with rituximab [abstract #170]. Kidney Blood Press Res 28
28. Kallenbach M et al. (2005) Rituximab induced remission in a patient with Wegener's granulomatosis. Nephron Clin Pract 99: c92-c96
29. Ferraro AJ et al. (2005) Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant 20: 622-625
30. Eriksson P (2005) Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257: 540-548
31. Keogh KA et al. (2006) Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173: 180-187
32. Aries PM et al. (2005) Lack of efficacy of Rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis [doi: 10.1136/ard.2005.044420]
33. Omdal R et al. (2005) Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 34: 229-232
34. Mandreoli M et al. (2004) Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. Am J Kidney Dis 44: 757-761
35. Yassa SK et al. (2005) Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome. Clin Transplant 19: 423-426
36. Chemnitz J et al. (2002) Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 71: 105-108
37. Stein GY et al. (2004) Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide. Int J Hematol 80: 94-96
38. Yomtovian R et al. (2004) Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 124: 787-795
39. Reddy PS et al. (2005) Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol 84: 232-235
40. Zheng X et al. (2003) Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 138: 105-108
41. Fakhouri F et al. (2005) Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 106: 1932-1937
42. Ganne V et al. (2003) Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant 17: 417-422
43. Al-Akash SI et al. (2005) Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy. Pediatr Transplant 9: 249-253
44. Book BK et al. (2005) New crossmatch technique eliminates interference by humanized and chimeric monoclonal antibodies. Transplant Proc 37: 640-642
45. Sarwal M et al. (2003) Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 349: 125-138
46. Alausa M et al. (2005) Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab. Clin Transplant 19: 137-140
47. Becker YT et al. (2004) Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 4: 996-1001
48. Samaniego M et al. (2002) Early allograft outcomes in patients with antibody mediated rejection treated with rituximab: a single center experience [abstract #259]. Am J Transplant 2 (Suppl 3)
49. Tyden G et al. (2005) ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 5: 145-148
50. Sonnenday CJ et al. (2004) Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 4: 1315-1322
51. Sawada T et al. (2002) Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 74: 1207-1210
52. Sawada T et al. (2004) Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled nonresponders to undergo ABO-incompatible kidney transplantation. Clin Transplant 18: 254-260
53. Gloor JM et al. (2005) A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 80: 1572-1577
54. Sidner RA et al. (2004) In vivo human B-cell subset recovery after in vivo depletion with rituximab, antihuman CD20 monoclonal antibody. Hum Antibodies 13: 55-62
55. Gloor JM et al. (2003) Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 3: 1017-1023
56. Choquet S et al. (2005) Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: results of a prospective multicentre phase II study. Blood [doi: 10.1182/blood-2005-01-0377]
57. Oertel SH et al. (2005) Effect of anti-CD20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 5: 2901-2906
58. Jain AB et al. (2005) Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation 80: 1692-1698
59. Gong Q et al. (2005) Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174: 817-826
60. Pijpe J et al. (2005) Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 52: 2740-2750
61. Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31: 456-473
62. Garrett HE Jr et al. (2005) Treatment of vascular rejection with rituximab in cardiac transplantation. J Heart Lung Transplant 24: 1337-1342